Prof Heinz-Josef Lenz speaks to ecancer at ASCO 2024 about the expanded efficacy analysis from CheckMate 8HW.
This study evaluates nivolumab plus ipilimumab versus chemotherapy as first-line treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer.
In the previous analysis, nivolumab plus ipilimumab demonstrated superior progression-free survival versus chemotherapy.
Prof Lenz reports that the clinical benefit with first line nivolumab plus ipilimumab versus chemotherapy was maintained after subsequent therapy, as shown by improved progression-free survival 2 in patients with centrally confirmed MSI-H/dMMR mCRC.